Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Status:
Completed
Trial end date:
2011-01-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed.
PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with
newly diagnosed stage II or stage IIIA breast cancer that can be removed by surgery.